Biotechnology

AIM ImmunoTech

Tencent

Financial Analysis

00700

AIMID

GOOG

GOOGL

NNOX

000656

TCTZF

TCEHY

80700

GGLS

GGLL

NANO

HTCD

SBCWW

After the Hong Kong stock market closed on November 13, Beijing time, $TENCENT(00700.HK) released its third-quarter 2025 results. Overall, while there were not many surprises compared to expectations, stability remains the key theme, with no significant weaknesses in the three major business lines. Since the beginning of this year, Tencent has entered a new investment cycle, yet traces of the management's refined operations and effective capital allocation can still be observed. Specifically: 1. Gaming remains the standout: Tencent Games maintained high growth of 23% in the third quarter, driven by the product cycle. Overseas, under the leadership of Supercell's 'Clash Royale,' it continued to surge (with favorable exchange rate contributions)...

TENCENT

Meta Platforms

AIM IMMUNOTECH INC

Alphabet - C

Alphabet

Nano-X Imaging

JINKE PROPERTY

SBC Medical

Tencent Holdings Limited

TENCENT-R

Direxion Daily Googl Bear 1x Shares

Direxion Daily GOOGL Bull 2X Shares

Pro Ultra 7-10Yrs

Nanoco Group PLC

Tencent HK SDR 10to1

SBC MEDICAL GROUP HOLDINGS INCRPRTD C/WTS 17/09/2029 (TO PUR COM)

Tencent: Not playing heartbeats with Meta, just seeking stable happiness

AIM ImmunoTech released FY2026 Q1 earnings on May 15 (EST), actual revenue USD 22K (forecast USD 0), actual EPS USD -0.6947 (forecast USD -0.37)

AIM ImmunoTech released FY2025 Q4 earnings on March 27 (EST), actual revenue USD 21K (forecast USD 0), actual EPS USD -1.4473 (forecast USD -0.939)

AIM ImmunoTech released FY2025 earnings on March 27 (EST), actual revenue USD 88 K (forecast USD 100 K), actual EPS USD -8.6234 (forecast USD -7.7422)

AIM ImmunoTech Inc Obtains Cancer Therapy Patent and Plans to Apply for Orphan Drug Status in Japan

AIM ImmunoTech Signs Agreement for Ampligen's Phase 3 Clinical Trial

AIM ImmunoTech Reports Q3 2025 Earnings and Pancreatic Cancer Project Progress

AIM ImmunoTech released FY2025 Q3 earnings on November 17 (EST), actual revenue USD 26K (forecast USD 0), actual EPS USD -1.5671 (forecast USD -0.975)

AIM ImmunoTech released FY2025 9 Months Earnings on November 17, 2025 (EST), with actual revenue of USD 67K and EPS of USD -10.5059

AIM ImmunoTech Delays Submission of Third Quarter Financial Report

AIM ImmunoTech Presents Phase II Clinical Trial Data for Ampligen in Treating Ovarian Cancer

AIM ImmunoTech Submits Revised Articles of Incorporation

Analyst Woo Covers Healthcare Sector Stocks

AIM Expands International Market Protection Through Patent Strategy and Seeks Cooperation and Revenue Growth

AIM ImmunoTech to Present Pancreatic Cancer Clinical Project Data at Marie Curie Congress

AIM ImmunoTech Reports Q2 2025 Financials with Increased Net Loss

AIM ImmunoTech released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 41K, actual EPS USD -8.8826

AIM ImmunoTech released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 25K (forecast USD 100K), actual EPS USD -3.676 (forecast USD -8)

AIM ImmunoTech Presents Ampligen Clinical Data at Annual Conference

AIM ImmunoTech's AMPLIGEN and IMFINZI Show Promising Results in Pancreatic Cancer

AIM ImmunoTech Patents Related to Ampligen

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

AMIX

MTVA

IBBQ

On Tuesday, Med Pharmaceuticals (NASDAQ:INM) saw a 127% increase to $1.54, while MetaVia (NASDAQ:MTVA) rose 58.54% to $1.76. Other gainers included Co-Diagnostics (NASDAQ:CODX) up 41.6% and Edesa Biotech (NASDAQ:EDSA) up 32.11%. Conversely, WORK Medical Tech Gr (NASDAQ:WOK) dropped 39% to $0.23, and Autonomix Medical (NASDAQ:AMIX) fell 25.43%. AIM ImmunoTech (AMEX:AIM) declined 18.02% to $0.33.

benzinga_article

Autonomix Medical

WORK Medical Tech

Edesa Biotech

Co-Diagnostics

iShares US Medical Devices

VanEck Biotech ETF

Health Care Select Sector SPDR

iShares Biotechnology ETF

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Adial Pharmaceuticals

Virax Biolabs

Akanda

Psyence Biomedical

Quantum Cyber NV

AIM ImmunoTech Inc.

PSYENCE BIOMEDICAL LTD C/WTS 25/01/2029(TO PUR COM)

Mainz Biomed NV

12 Health Care Stocks Moving In Tuesday's Intraday Session

ARKG

AIM ImmunoTech Inc. announced a significant increase in stockholder equity to approximately $2.1 million and extended the maturity date of its promissory note to June 30, 2027. This extension enhances the company's financial flexibility, supporting its pancreatic cancer development strategy. The CEO expressed confidence in the company's ability to manage capital resources and achieve near-term milestones, which could create stockholder value.

StockTitan

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VG Health

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Global Healthcare

iShares US Pharma

AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities | AIM Stock News

BLRX

NCNA

PMCB

In Monday's after-market session, BioLine Rx (BLRX) gained 12.5% to $3.11, while CDT Equity (CDT) rose 9.35% to $1.64. NuCana (NCNA) increased by 7.88% to $2.19. AIM ImmunoTech (AIM) fell 16.8% to $0.34, and Picard Medical (PMI) dropped 14.37% to $0.15. Other notable movements included PharmaCyte Biotech (PMCB) up 7.49% and WORK Medical Tech (WOK) down 10.53%. Q1 earnings reports influenced these stock changes.

Bioline RX

Nucana

CDT Equity

Picard Medical

PharmaCyte Biotech

CapsoVision

Polaryx Therapeutics

Sunshine Biopharma

Atlantic

CDT EQUITY INC C/WTS 22/09/2028(TO PUR COM)

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

ATLANTIC INTERNATIONAL CORP C/WTS 31/08/2026 (TO PUR COM)

12 Health Care Stocks Moving In Monday's After-Market Session

AIM ImmunoTech shares are trading higher. The company reported Q1 financial results.

GOSS

LTRN

In Monday's pre-market session, Sunshine Biopharma surged 635.6% to $2.09, while Geovax Labs rose 169.91% to $3.32. Other gainers included Virax Biolabs (+100.71%), AIM ImmunoTech (+45.73%), and Quantum Cyber (+17.05%). Conversely, WORK Medical Tech fell 25.5%, P3 Health Partners dropped 22.53%, and Artelo Biosciences decreased by 17.4%. Citius Pharmaceuticals, Gossamer Bio, and Lantern Pharma also saw declines following their Q1 earnings reports.

Gossamer Bio

Lantern Pharma

P3 Health Partners

Citius Pharma

GeoVax Labs

Artelo Biosciences

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM)

P3 HEALTH PARTNERS INC C/WTS 19/11/2026 (TO PUR COM)

12 Health Care Stocks Moving In Monday's Pre-Market Session

Earnings Watch

AIM ImmunoTech | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 22 K

AIM ImmunoTech Inc. announced a Virtual Investor KOL segment featuring Professor Casper H.J. van Eijck discussing Ampligen's progress in treating late-stage pancreatic cancer. The segment highlights positive interim data from the ongoing Phase 2 clinical trial (DURIPANC) and improvements in survival rates compared to historical controls. The company aims to advance Ampligen as a potential treatment option, with further reports expected in June 2026. AIM ImmunoTech focuses on developing Ampligen for this critical health issue, showcasing its commitment to addressing unmet medical needs in pancreatic cancer.

Proshares Ultra Nasdaq Biotech

AstraZeneca

AstraZeneca PLC

AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer | AIM Stock News

MRVI

In Friday's trading session, several health care stocks experienced significant movements. AMN Healthcare Services surged 25.6% to $28.2, while Inovio Pharmaceuticals and Maravai LifeSciences rose 25.28% and 23.22%, respectively. Conversely, AIM ImmunoTech saw a sharp decline of 35.1% to $0.36, with Artivion and Sensus Healthcare also falling by 26.6% and 26.53%. The Q1 earnings reports for many of these companies were released yesterday, influencing stock performance.

AIM ImmunoTech(AIM.US)